DiaMedica Therapeutics Inc. Profile Avatar - Palmy Investing

DiaMedica Therapeutics Inc.

DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, develops treatments for neurological and kidney diseases. The company's lead drug candidate is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase 2 REDUX tria…

Biotechnology
US, Minneapolis [HQ]

Document Reader

Click To Read:

DEF 14-A Proxies

Not a single DEF 14-A proxy doc.

10-K Filings

Not a single 10-K doc.

10-Q Filings

Not a single 10-Q doc.

LDA 1/2 Filings [Lobbying]

Not a single LDA doc.

End of DMAC's Analysis
CIK: 1401040 CUSIP: 25253X207 ISIN: CA25253X2077 LEI: - UEI: -
Secondary Listings
DMAC has no secondary listings inside our databases.